All articles tagged with #alcohol dependence
New research reveals that fewer than 500 neurons in the brain are responsible for suppressing binge drinking, using advanced neurotechnologies to identify and manipulate these specific neural ensembles, which could lead to targeted therapies for alcohol addiction.
A compound called LY2444296, which blocks the kappa opioid receptor, has shown promise in significantly reducing alcohol consumption and withdrawal symptoms in animal models of alcohol dependence. This compound could potentially offer a breakthrough in treating alcohol use disorder (AUD) by targeting the brain’s KOP system. The research, funded by the National Institute on Alcohol Abuse and Alcoholism, suggests that LY2444296 and similar compounds may provide new treatment avenues for AUD by focusing on the specific brain circuits involved in addiction and withdrawal.
A new study has found that Semaglutide, a drug used to treat obesity and diabetes, significantly reduced alcohol consumption and relapses in alcohol-dependent rats by blocking alcohol-induced dopamine release in the brain's reward system. Clinical studies on humans are needed to confirm these findings, but the medication may be of most benefit to patients suffering from both overweight and alcohol dependence. Semaglutide is a long-acting substance that only needs to be taken once a week and is the first medication to act on the GLP-1 receptor that can be taken in tablet form.
Semaglutide, a medication used for type 2 diabetes and obesity, has shown potential as a treatment for alcohol dependence. The drug reduced alcohol relapse drinking and overall alcohol intake in rats by more than half. Semaglutide acts on the GLP-1 receptor and is taken in tablet form once a week. Clinical studies are needed to confirm the findings in humans, but the results offer promising insights into potential additional treatment options for alcohol dependence.